Poliovirus type 2 antigen (formaldehyde inactivated)

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Brand Names
Ipol, Kinrix, Pediarix, Pentacel, Quadracel, Vaxelis
Generic Name
Poliovirus type 2 antigen (formaldehyde inactivated)
DrugBank Accession Number
DB10796
Background

Poliovirus type 2 antigen is a suspension of poliovirus Type 2 (MEF-1) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 2. The vaccine contains purified and inactivated poliovirus type 2 that were grown from a continuous line of monkey kidney cells.

Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Vaccines
Inactivated
Synonyms
  • Inactivated poliomyelitis vaccine (D.C.O.) type 2 MEF1
  • Inactivated poliomyelitis vaccine (V.C.O.) type 2 MEF1
  • Inactivated poliovirus type II
  • Poliovirus vaccine inactivated, type 2 (MEF-1)

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Prevention ofPoliomyelitis caused by poliovirus••••••••••••
Prevention ofPoliomyelitis caused by poliovirus••••••••••••
Prevention ofPoliomyelitis caused by poliovirus type 2••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
ADACEL POLIO 0,5 ML IM ENJEKSİYON İÇİN SÜSPANSİYON İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADETPoliovirus type 2 antigen (formaldehyde inactivated) (8 DU/5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (5 mcg/0.5mL) + Bordetella pertussis fimbriae 2/3 antigen (5 mcg/0.5mL) + Bordetella pertussis pertactin antigen (3 mcg/0.5mL) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (2.5 mcg/0.5mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 Lf/0.5mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (2 Lf/0.5mL) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 DU/5mL) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 DU/5mL)Injection, suspensionIntramuscularSANOFİ PASTEUR AŞI TİC. A.Ş.2008-12-302022-08-23Turkey flag
ADACEL- POLIOPoliovirus type 2 antigen (formaldehyde inactivated) (8 [D'ag'U]/0.5ml) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (5 ug/0.5mL) + Bordetella pertussis fimbriae 2/3 antigen (5 ug/0.5mL) + Bordetella pertussis pertactin antigen (3 ug/0.5mL) + Bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (2.5 ug/0.5mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 [Lf]/0.5mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (2 [Lf]/0.5mL) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 [D'ag'U]/0.5ml) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 [D'ag'U]/0.5ml)Injection, suspensionIntramuscularSANOFI-AVENTIS (MALAYSIA) SDN. BHD.2020-09-082024-02-24Malaysia flag
Adacel-polioPoliovirus type 2 antigen (formaldehyde inactivated) (8 unit / 0.5 mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (5 mcg / 0.5 mL) + Bordetella pertussis fimbriae 2/3 antigen (5 mcg / 0.5 mL) + Bordetella pertussis pertactin antigen (3 mcg / 0.5 mL) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (2.5 mcg / 0.5 mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 lf / 0.5 mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (2 lf / 0.5 mL) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 unit / 0.5 mL) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 unit / 0.5 mL)SuspensionIntramuscularSanofi Pasteur Limited2011-03-11Not applicableCanada flag
ADACEL?-POLIO SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGEPoliovirus type 2 antigen (formaldehyde inactivated) (8 D'ag'U) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (5 mcg/0.5 ml) + Bordetella pertussis fimbriae 2/3 antigen (5 mcg/0,5 ml) + Bordetella pertussis pertactin antigen (3 mcg/0.5 ml) + Bordetella pertussis toxoid antigen (formaldehyde inactivated) (2.5 mcg/0.5ml) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 Lf) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (2 Lf) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 D'ag'U) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 D'ag'U)Injection, suspensionIntramuscularSANOFI-AVENTIS SINGAPORE PTE. LTD.2018-08-05Not applicableSingapore flag
Boostrix Polio - Injektionssuspension in einer FertigspritzePoliovirus type 2 antigen (formaldehyde inactivated) (8 [D'ag'U]/0.5ml) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (8 mcg/0.5ml) + Bordetella pertussis pertactin antigen (2.5 mcg/0.5ml) + Clostridium tetani (20 IU/0.5ml) + Corynebacterium diphtheriae (2 IU/0.5ml) + Pertussis vaccine (8 mcg/0.5ml) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 [D'ag'U]/0.5ml) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 [D'ag'U]/0.5ml)Injection, solutionIntramuscularGlaxo Smith Kline Pharma Gmb H2004-11-05Not applicableAustria flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
23JE9KDF4R
CAS number
Not Available

References

General References
Not Available
PubChem Substance
347910902
RxNav
763098

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns
4CompletedPreventionAcellular Pertussis / Diphtheria / Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines / Haemophilus Influenzae Serotype b (Hib) / Poliomyelitis / Tetanus / Viral Hepatitis B1somestatusstop reasonjust information to hide
4CompletedPreventionAcellular Pertussis / Diphtheria / Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines / Poliomyelitis / Tetanus1somestatusstop reasonjust information to hide
4CompletedPreventionAcellular Pertussis / Diphtheria / Poliomyelitis / Tetanus1somestatusstop reasonjust information to hide
4CompletedPreventionAcellular Pertussis / Diphtheria / Poliomyelitis / Tetanus / Viral Hepatitis B1somestatusstop reasonjust information to hide
4CompletedPreventionAcute Lymphoblastic Leukemia (ALL)1somestatusstop reasonjust information to hide

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, solutionIntramuscular
InjectionIntramuscular; Subcutaneous
SolutionSubcutaneous
Injection, suspensionIntramuscular; Subcutaneous
Injection
SuspensionIntramuscular
Injection, suspensionIntramuscular
Injection; injection, suspension; kitIntramuscular
Injection, powder, for suspensionIntramuscular
InjectionIntramuscular
Injection, suspensionIntramuscular30 iu/0.5ml
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at December 01, 2015 20:04 / Updated at November 28, 2021 16:22